KLRS
NASDAQKalaris Therapeutics Inc.
News · 26 weeks45+67%
2025-12-142026-06-07
Mix3390d
- SEC Filings16(48%)
- Insider12(36%)
- Other3(9%)
- Analyst2(6%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Jovan-Embiricos Morana4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Director Ferrara Napoleone4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Director Hallal David4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Director Akkaraju Srinivas4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Director Dybbs Michael4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Director Adamis Anthony P4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Director Patterson Leone D4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- SECSEC Form 8-K filed by Kalaris Therapeutics Inc.8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Kalaris Therapeutics Inc.SCHEDULE 13D/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)
- INSIDERDirector Akkaraju Srinivas bought $1,179,969 worth of shares (244,300 units at $4.83), disposed of 66,906 shares and acquired 19,408 shares (SEC Form 4)4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- ANALYSTWedbush initiated coverage on Kalaris Therapeutics with a new price targetWedbush initiated coverage of Kalaris Therapeutics with a rating of Outperform and set a new price target of $17.00
- SECSEC Form 10-Q filed by Kalaris Therapeutics Inc.10-Q - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form 8-K filed by Kalaris Therapeutics Inc.8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- PRKalaris Reports First Quarter 2026 Financial Results and Provides Business UpdatesPatient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027 Planned Phase 3 clinical trials remain on track for 2027 year-end initiation $104.9 million in cash, cash equivalents and marketable securities as of March 31, 2026 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseas
- SECSEC Form DEFA14A filed by Kalaris Therapeutics Inc.DEFA14A - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form DEF 14A filed by Kalaris Therapeutics Inc.DEF 14A - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- ANALYSTMorgan Stanley initiated coverage on Kalaris Therapeutics with a new price targetMorgan Stanley initiated coverage of Kalaris Therapeutics with a rating of Overweight and set a new price target of $14.00
- SECSEC Form EFFECT filed by Kalaris Therapeutics Inc.EFFECT - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form EFFECT filed by Kalaris Therapeutics Inc.EFFECT - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form 424B3 filed by Kalaris Therapeutics Inc.424B3 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form 424B3 filed by Kalaris Therapeutics Inc.424B3 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form 8-K filed by Kalaris Therapeutics Inc.8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form S-3 filed by Kalaris Therapeutics Inc.S-3 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form S-3 filed by Kalaris Therapeutics Inc.S-3 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- INSIDERSEC Form 4 filed by Hagen Brett R4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
KLRS FAQ
6 questionsWhere does KLRS stock trade?
Kalaris Therapeutics Inc. (KLRS) is listed on NASDAQ.What sector and industry is KLRS in?
Kalaris Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Kalaris Therapeutics Inc. go public?
Kalaris Therapeutics Inc. (KLRS) completed its IPO in 2020.What are analysts saying about KLRS?
Kalaris Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wedbush: Outperform with a $1700.00 price target on 2026-05-14.What companies are similar to KLRS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare KLRS side-by-side with any of them on Quantisnow.How can I track KLRS on Quantisnow?
Quantisnow aggregates Kalaris Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KLRS to receive live email and push alerts on every new disclosure.